Decoy Therapeutics
DCOY
8 hedge funds and large institutions have $104K invested in Decoy Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
115% more capital invested
Capital invested by funds: $48.4K → $104K (+$55.6K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
60% more funds holding
Funds holding: 5 → 8 (+3)
0.01% more ownership
Funds ownership: 0.02% → 0.03% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$24.8K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$13.1K |
| 3 |
Goldman Sachs
New York
|
+$13.1K |
| 4 |
Barclays
London,
United Kingdom
|
+$6.33K |
| 5 |
Citigroup
New York
|
+$4.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.2K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$11.6K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$141 |
DCOY Hedge Fund Activity: Q2 2025 in Review
8 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2025, worth a combined $104K — up 115% from $48.4K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DCOY positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $24.8K. The largest seller was UBS Group, cutting an estimated $12.2K.
- 8 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2025, up from 5 in Q1 2025.
- Funds reported $104K of Decoy Therapeutics stock for Q2 2025, up 115% quarter-over-quarter.
- 5 funds opened new Decoy Therapeutics positions in Q2 2025 and 2 closed out, a net change of +3 holders.
- The largest Decoy Therapeutics buyer in Q2 2025 was HRT Financial, an estimated $24.8K added.
- The largest Decoy Therapeutics seller in Q2 2025 was UBS Group, an estimated $12.2K sold.
Based on aggregated 13F filings for Q2 2025.